Combined chemotherapy and radiotherapy in inoperable non-small cell lung cancer

Lung Cancer

Volumn 38, Issue 3 SUPPL., 2002, Pages 43-46

  Jassem, Jacek ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

Chemotherapy; Non small cell lung cancer; Radiotherapy

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; LOMUSTINE; METHOTREXATE; MITOMYCIN; NAVELBINE; TAXANE DERIVATIVE; VINBLASTINE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; HUMAN; INOPERABLE CANCER; LUNG NON SMALL CELL CANCER; META ANALYSIS; METASTASIS; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; TOXICITY; TREATMENT OUTCOME; TUMOR LOCALIZATION;

EID: 0036896367     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0169-5002(02)00267-2     Document Type: Article

References (26)

1. Hoffman P.C., Maurer A.M., Vokes E.V. Lung cancer. Lancet. 355:2000;479-485.
2. Mattson K., Holsti L.P., Holsti P., et al. Inoperable non-small cell lung cancer: radiation with or without chemotherapy. Eur. J. Cancer Clin. Oncol. 24:1988;477-482.
3. Morton R.F., Jett J.R., McGinnis W.L., et al. Thoracic radiation therapy alone compared with chemoradiotherapy for locally unresectable non-small cell carcinoma of the lung. Ann. Intern. Med. 115:1991;681-686.
4. Le Chevalier T., Arriagada R., Tarayre M., et al. Significant effect of adjuvant chemotherapy on survival in locally advanced non-small-cell lung carcinoma (letter). J. Natl. Cancer Inst. 8:1992;58.
5. Dillman R.O., Herndon J., Seagren S.L., et al. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B [CALGB] 8433 trial. J. Natl. Cancer Inst. 88:1996;1210-1214.
6. Sause W., Kolesar P., Taylor S., et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer. Chest. 117:2000;358-364.
7. Brodin O., Nou E., Mercke C., et al. Comparison of induction chemotherapy before radiotherapy with radiotherapy only in patients with locally advanced squamous cell carcinoma of the lung. Eur. J. Cancer. 32(11):1996;1893-1900.
8. Cullen M.H., Billingham L.J., Woodrofee C.M., et al. Mitomycin, ifosfamide and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J. Clin. Oncol. 17:1999;3188-3194.
9. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br. Med. J. 311:1995;899-909.
10. Schaake-Koning C., Van den Bogaert W., Dalesio O., et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small cell lung cancer. N. Engl. J. Med. 326:1992;524-530.
11. Trovo N.G., Minotel E., Fravelun G., et al. Radiotherapy versus radiotherapy enhanced by cisplatin in stage III non-small cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 24:1992;11-16.
12. Ball D., Bishop J., Smith J., et al. A randomized phase III study of accelerated or standard fraction radiotherapy with or without concurrent carboplatin in inoperable non-small cell lung cancer: final report of an Australian multi-centre trial. Radiother. Oncol. 52:1999;129-136.
13. Clamon G., Herndon J., Cooper R., et al. Radiosensitization with carboplatin for patients with unresectable stage III non-small cell lung cancer: a phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group. J. Clin. Oncol. 17:1999;4-11.
14. Blanke C., Ansari R., Montravadi R., et al. A phase III trial of thoracic irradiation with and without concomitant cisplatin for locally advanced unresectable non-small cell lung cancer: A Hoosier Oncology Group study. J. Clin. Oncol. 13:1995;1425-1429.
15. Trovo M.G., Minatel E., Veronesi A., et al. Combined radiotherapy and chemotherapy versus radiotherapy alone in locally advanced epidermoid bronchogenic carcinoma. A randomized study. Cancer. 65:1990;400-404.
16. Jeremic B., Shibamoto Y., Acimovic L., et al. Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer. J. Clin. Oncol. 13:1995;452-458.
17. Jeremic B., Shibamoto Y., Acimovic L., et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: a randomized study. J. Clin. Oncol. 14:1996;1065-1070.
18. Furuse K., Fukuoka M., Kawahara M., et al. Phase III study of concurrent vs. sequential thoracic radiotherapy in combination with mitomycin, vindesine and cisplatin in unresectable stage III non-small cell lung cancer: five-year median follow-up results. J. Clin. Oncol. 17:1999;2692-2699.
19. Movsas B., Scott C., Curran W. A quality-adjusted time without symptoms or toxicity (QTWiST). Analysis of Radiation Therapy Oncology Group [RTOG] 9410 [abstract]. Proc. Am. Soc. Clin. Oncol. 20:2001;313a.
20. Mornex F., Robinet G., Thomas P., et al. Sequential versus concurrent chemo-radiation (RT-CT) in locally advanced non small cell lung cancer (NSCLC): a French randomized phase III trial of GLOT-GFPC (NPC 95-01 study). Eur. J. Cancer. 37:(Suppl. 6):2001;S29.
21. Jassem J. Chemotherapy of advanced non-small cell lung cancer. Ann. Oncol. 10:(Suppl. 6):1999;S77-S82.
22. Vokes E.E., Leopold K.A., Herndon J.E., et al. CALGB Study 9431: a randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy (Ind CT) and concomitant chemoradiotherapy (XRT) for unresectable stage III non-small cell lung cancer (NSCLC). Lung Cancer. 29:(Suppl. 1):2000;49.
23. Jassem J. Combined chemotherapy and radiation in locally advanced non-small cell lung cancer. Lancet Oncol. 2:2001;335-342.
24. Komaki R., Scott C.B., Sause T., et al. Induction cisplatin/vinblastine and irradiation vs. irradiation in unresectable squamous cell lung cancer: failure patterns by cell type in RTOG 88-08/ECOG 4588. Int. J. Rad. Oncol. Biol. Phys. 39:1997;537-544.
25. Furuse K., Hosoe S., Masuda N., et al. Impact of tumor control on survival in unresectable stage III non-small cell lung cancer (NSCLC) treated with concurrent thoracic radiotherapy (TRT) and chemotherapy (CT) [abstract]. Proc. Am. Soc. Clin. Oncol. 19:2000;484a.
26. Saunders M., Dische S., Barrett A., et al. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial. Lancet. 350:1997;161-165.